CardioMech develops a catheter-based device that utilizes artificial chords to reduce mitral regurgitation, a condition characterized by the backward flow of blood across the mitral valve. This technology offers a less invasive alternative to open-heart surgery for patients with structural heart disease, potentially improving outcomes and reducing recovery times.
Funding
$54.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Mitral regurgitation, a condition where blood flows backward across the mitral valve, is a highly prevalent and debilitating cardiovascular disease that can be deadly if left untreated. Current treatment options often involve invasive open-heart surgery, which may not be suitable for all patients, or watchful waiting, which can delay necessary intervention.
Solution
CardioMech is developing a catheter-based device that utilizes artificial chords to reduce or eliminate mitral regurgitation and restore the native anatomy of the mitral valve. This percutaneous therapy offers a less invasive alternative to open-heart surgery for a broader range of patients, including those ineligible for surgery. The device is designed to be easily inserted and straightforward to use, potentially reducing the need for open-heart procedures and lessening the reliance on watchful waiting, especially in younger, healthier individuals.
Target Audience
The primary target audience includes patients with mitral regurgitation, interventional cardiologists, cardiac surgeons, and hospitals specializing in structural heart disease treatments.
Features
- Catheter-based delivery system for minimally invasive implantation.
- Artificial chords designed to reduce or eliminate mitral regurgitation.
- Designed to restore the native anatomy of the mitral valve.
- Intended as a straightforward procedure for ease of use.
- Potential applicability to patients both eligible and ineligible for open-heart surgery.